company background image
RX

BioSyent TSXV:RX Stock Report

Last Price

CA$7.03

Market Cap

CA$85.1m

7D

-2.4%

1Y

-19.2%

Updated

07 Dec, 2022

Data

Company Financials +
RX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends0/6

RX Stock Overview

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.

BioSyent Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioSyent
Historical stock prices
Current Share PriceCA$7.03
52 Week HighCA$10.00
52 Week LowCA$6.24
Beta0.80
1 Month Change-0.99%
3 Month Change-12.67%
1 Year Change-19.20%
3 Year Change-2.23%
5 Year Change-28.27%
Change since IPO1,462.22%

Recent News & Updates

Recent updates

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Shareholder Returns

RXCA PharmaceuticalsCA Market
7D-2.4%3.8%-1.5%
1Y-19.2%-46.8%-3.4%

Return vs Industry: RX exceeded the Canadian Pharmaceuticals industry which returned -46.8% over the past year.

Return vs Market: RX underperformed the Canadian Market which returned -3.4% over the past year.

Price Volatility

Is RX's price volatile compared to industry and market?
RX volatility
RX Average Weekly Movement7.9%
Pharmaceuticals Industry Average Movement14.1%
Market Average Movement9.9%
10% most volatile stocks in CA Market18.2%
10% least volatile stocks in CA Market4.1%

Stable Share Price: RX is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: RX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aRené Goehrumhttps://www.biosyent.com

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum.

BioSyent Inc. Fundamentals Summary

How do BioSyent's earnings and revenue compare to its market cap?
RX fundamental statistics
Market CapCA$85.06m
Earnings (TTM)CA$6.14m
Revenue (TTM)CA$27.68m

13.9x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RX income statement (TTM)
RevenueCA$27.68m
Cost of RevenueCA$5.20m
Gross ProfitCA$22.49m
Other ExpensesCA$16.35m
EarningsCA$6.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.51
Gross Margin81.23%
Net Profit Margin22.17%
Debt/Equity Ratio0%

How did RX perform over the long term?

See historical performance and comparison